GLP-1 drugs are changing more than what people eat. They may also be changing how consumers think about weight management, health, wellbeing and the support they need along the way.
A brief asking for ‘GLP-1 users’ can sound specific. It still leaves a lot unanswered.
But who exactly does that include?
It could mean someone considering treatment, someone three months in, someone who has stopped, or someone who wanted to start but couldn’t.
They may all sit within the GLP-1 conversation, but their motivations and experiences could be very different.
We’ve already explored what GLP-1s could mean for food purchasing and FMCG behaviour. But there’s a much bigger consumer health story emerging – around why people start, what they hope to achieve and how their needs may change over time.
What are GLP-1 drugs?
GLP-1 receptor agonists are prescription medicines that mimic the action of a naturally occurring hormone involved in appetite regulation. They can help some people feel fuller for longer, reduce hunger and experience fewer cravings.
But there is no single GLP-1 experience. Treatments differ, side effects vary and outcomes are not the same for everyone.
The formats are changing too. In June 2026, the MHRA approved the UK’s first GLP-1 receptor agonist tablet for weight loss and weight management, an oral form of semaglutide. In August, it authorised orforglipron, another GLP-1 tablet, for weight management and type 2 diabetes.
This article looks at what that changing landscape could mean for consumer health research; it does not provide medical advice.
Weight management is becoming a broader healthcare decision
GLP-1 research isn’t only about whether somebody takes medication. It can also be about everything that happens around that decision.
Consumers may be weighing up healthcare advice alongside online providers, pharmacies, nutrition support, fitness programmes and apps.
That decision might begin with a GP conversation, a friend’s experience or something seen on TikTok. Cost, eligibility, perceived risks and trust could all shape what happens next.
Research that starts at the point of purchase or prescription could miss what shaped the decision.
GLP-1 drugs may change how consumers define success
Weight-management research has traditionally focused heavily on weight lost, appearance, restraint or motivation.
Our Angelfish pulse survey of current and former GLP-1 users gives an indication. Some 67% said previous weight-loss approaches had not worked for them, 57% wanted help managing appetite or cravings, 48% wanted to improve their general health and 37% wanted better mobility or energy levels.
Success might mean fewer cravings, more energy, improved mobility, greater confidence or finding a way to maintain progress over time.
One respondent raised the question of support after treatment:
“There is lots of support for starting but very little about maintaining your weight afterwards.”
Our pulse survey was community-based rather than nationally representative, but those experiences raise useful questions about what consumers may need beyond the medication itself.
Ask participants what progress means to them before choosing the measures for it.
Why “GLP-1 users” are not one research segment
A brief asking for “people who use GLP-1 medication” might sound specific. In reality, it can still bring together people with very different experiences.
Depending on the research objective, it may be useful to separate:
- current, former and prospective users
- people at different stages of treatment
- injection and tablet users
- different access routes or providers
- people who have experienced interruptions or side effects
- different reasons for starting or stopping.
Non-users matter too. Someone may be interested but ineligible, worried about side effects, unable to afford treatment or simply uncomfortable with medication-led weight management.
There is no single “right” GLP-1 segment.
The right audience is the one that matches the behaviour, experience or decision the research needs to understand.
What does this mean for GLP-1 market research?
Screen for the journey, not just the label. A yes-or-no question about GLP-1 use may not be enough. Status, duration, previous use and access route could all affect eligibility. At the same time, researchers should only collect health information that is necessary and relevant to the project.
Build segmentation around the research question. Broad labels such as “dieters” or “weight-conscious consumers” can hide important differences in motivation and experience.
Watch the language. Avoid questions that imply failure, lack of willpower or that medication is an “easy option”. Participants need room to share positive, negative and mixed experiences.
Moderate sensitively. Weight, body image, health and medication are personal subjects. Neutral, non-judgemental communication matters from recruitment onwards.
Consider what changes over time. Methods such as digital ethnography, online communities and repeat depth interviews can help researchers understand changing expectations, behaviours and support needs rather than capturing a single moment.
Why should consumer health brands care?
GLP-1 use could raise new research questions across nutrition, supplements, digestive health, muscle maintenance, fitness, mental wellbeing, skincare, sleep, digital health and long-term weight management.
The aim isn’t to predict that GLP-1 drugs will transform every consumer health category. It’s to understand whether needs are changing, where gaps are appearing and what consumers actually want next.
Our pulse survey, for example, pointed towards interest in greater nutritional value, smaller formats, energy and muscle maintenance, as well as practical support after treatment. The findings offer useful starting points for research, but each audience and product category will need testing on its own terms.
How Angelfish supports GLP-1 research
At Angelfish Fieldwork, we help consumer health researchers define and recruit the people behind complex and sensitive health journeys.
For GLP-1 and weight-management research, that could mean distinguishing current, former, prospective and non-users; recruiting around treatment stage or access route; developing suitable screening criteria; and validating participants carefully.
We support participant recruitment for interviews, focus groups, digital diaries, online communities and digital ethnography – with the audience shaped around what the study genuinely needs to understand.
Want to learn more about how consumers are experiencing GLP-1 treatment? See the results of our GLP-1 pulse survey to explore the motivations, challenges and support needs identified by current and former users.
Planning GLP-1 or weight management research of your own? Talk to Angelfish about recruiting the right participants for your study.
Further reading
